Elevance Health Earnings Call Highlights Growth, Key Risks

Elevance Health, Inc. ((ELV)) has held its Q1 earnings call. Read on for the main highlights of the call.

Elevance Health’s latest earnings call struck a cautiously upbeat tone, as management balanced a clean Q1 earnings beat and a raised long‑term EPS target against a sizable regulatory accrual and persistent Medicaid headwinds. Investors heard a story of strong execution, rising cash generation, and early AI payoffs, tempered by known, largely manageable risks.

Adjusted EPS Beat and Upgraded Long-Term Guidance

Elevance posted Q1 adjusted diluted EPS of $12.58, comfortably ahead of expectations and strong enough to support a higher long‑term outlook. The company raised its 2026 adjusted EPS guidance to at least $26.75, framing a normalized baseline of $25.75 and targeting a return to 12% or better EPS growth in 2027.

Membership and Revenue Growth

Membership ended March at 45.4 million, up roughly 200,000 lives from year‑end, showing the franchise can still grow even in a choppy public‑program backdrop. Operating revenue rose 1.5% year over year to $49.5 billion, as lower plan membership in some segments offset healthy premium yields.

Expense Discipline and Strong Cash Generation

Cost control helped underpin the quarter, with the consolidated benefit expense ratio at 86.8% and the adjusted operating expense ratio improving 20 basis points to 10.5%. Operating cash flow reached $4.3 billion in Q1, putting the company on solid footing to hit its full‑year target of at least $5.5 billion.

Capital Deployment and Share Repurchases

Management continued to lean into buybacks, repurchasing 3.7 million shares for $1.1 billion at just over $300 per share. They reiterated a plan for at least $2.3 billion of repurchases in 2026, reinforcing a shareholder‑friendly capital allocation stance alongside internal investments.

Carelon and CareBridge Clinical Impact

The services arm continued to demonstrate clinical value, with integrated CareBridge and Care at Home programs cutting hospital readmissions by 20%. These offerings also delivered more than 10% savings on post‑acute care, strengthening the case for risk‑based, whole‑person solutions that can win business beyond Elevance’s own plans.

Medicare and Commercial Momentum

Medicare Advantage results improved, keeping the company on course for an operating margin of at least 2% in 2026 in a tougher regulatory environment. In commercial, selling momentum remains robust, with a record‑level pipeline for 2027 and fresh employer wins for combined medical‑pharmacy products.

AI and Digital Investments Showing Early Traction

Elevance is deploying more than $1 billion into digital and AI tools, and early usage metrics suggest traction. A virtual AI assistant now supports about 22 million commercial members, while a provider‑matching engine has engaged over 20% of members and AI‑driven workflows have cut prior‑authorization denials by roughly 70% in certain cases.

Positive Cash Dynamics and Prior-Year Development

Management highlighted around $250 million of favorable prior‑year development in Q1, while stressing its limited impact on the overall profit and loss. They also reaffirmed the at‑least $5.5 billion operating cash flow goal for the year, inclusive of potential outflows tied to regulatory matters.

CMS Risk-Adjustment Accrual and Regulatory Uncertainty

A key overhang is a $935 million accrual recorded in Q1 for historical risk‑adjustment data under review by CMS, which weighed on reported results but is framed as a one‑time issue. The company is actively engaged with regulators and working through required compliance steps, though the final settlement amount and timing remain uncertain.

Business Optimization Charge

Elevance also booked a $129 million business optimization charge in Q1, tied to organizational simplification and related restructuring moves. Management cast these actions as necessary to streamline operations and better support long‑term growth and margin targets.

Carelon Margin and Earnings Dynamics

Despite strong clinical results, Carelon’s operating gain dipped modestly year over year, pressured by lower affiliated health plan membership and heavy investment in risk‑based capabilities. Margins fell short of earlier expectations for Q1, but the company still guides to mid‑5% margins at Carelon Rx for the full year.

Medicaid Pressure and Membership Headwinds

Medicaid remains a trouble spot as underlying cost trends stay elevated even with early gains in behavioral health and specialty pharmacy management. Elevance expects high single‑digit Medicaid membership declines in 2026 amid eligibility reviews, with full‑year Medicaid margins running at approximately negative 1.75%.

Seasonality and ACA Product Mix Timing

Management cautioned that about one‑third of the Q1 outperformance was seasonal and tied to a heavier mix of Individual ACA bronze plans, which push more medical costs into the back half of the year. Investors should therefore expect some normalization as costs catch up, even as the company looks to be roughly 1.2 million ACA members ahead of plan at Q2.

Working Capital and Claims Payable Trends

Operationally, days in claims payable rose to 46.6 days, up 5.3 days sequentially, driven largely by seasonal patterns and higher medical claims inventory. While this cushions near‑term cash, it also reflects a more elevated claims environment that management will need to monitor closely.

Guidance and Outlook

Looking ahead, Elevance expects Q2 EPS to represent about 23% of its revised full‑year guidance and continues to target at least $5.5 billion in operating cash flow and at least $2.3 billion of 2026 buybacks. The company also reaffirmed key segment metrics, including mid‑5% margins at Carelon Rx, a roughly negative 1.75% Medicaid margin, and at least 2% Medicare Advantage margins in 2026, underpinned by a 2026 EPS floor of $26.75 and a 2027 growth goal of 12% or more.

Elevance’s earnings call painted a picture of a diversified health‑care giant leaning on execution, services growth, and AI to drive value despite policy and Medicaid noise. For investors, the raised long‑term EPS bar, robust cash generation, and tangible digital traction provide reasons for optimism, even as the CMS review and public‑program economics remain key risks to watch.